ProfileGDS5678 / 1419810_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 78% 76% 85% 75% 75% 80% 75% 75% 74% 74% 76% 74% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0320376
GSM967853U87-EV human glioblastoma xenograft - Control 25.3896378
GSM967854U87-EV human glioblastoma xenograft - Control 35.0846776
GSM967855U87-EV human glioblastoma xenograft - Control 46.5931285
GSM967856U87-EV human glioblastoma xenograft - Control 54.9652675
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8264275
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4716880
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9875475
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9156275
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8806474
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8334274
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.158376
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7656674
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2708277